Extended Vancomycin Pulse–Taper Regimen May Reduce Early CDI Recurrence: Study
Written By : Medha Baranwal
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2026-03-04 15:15 GMT | Update On 2026-03-04 15:15 GMT
Canada: Researchers have found in a new randomized clinical trial that a 4-week vancomycin pulse and taper regimen showed a 73.8% probability of superiority compared with a 2-week pulse regimen. The findings suggest that the longer pulse–taper approach may be a safe, effective, and accessible strategy to delay or prevent early recurrence of Clostridioides difficile infection (CDI).
The trial, published in JAMA Network Open, was conducted by Emily G. McDonald from the Division of General Internal Medicine at McGill University, Montréal, Canada, and colleagues. CDI remains a major cause of illness and death, particularly in hospitalized and older patients, and recurrence after initial treatment is common. The investigators aimed to determine whether extending vancomycin therapy using a pulse and taper strategy could reduce the risk of recurrent CDI (rCDI) among patients experiencing a first episode or first recurrence.
The double-blind, parallel-group randomized clinical trial was conducted at 12 Canadian hospitals. Adults with clinically and laboratory-confirmed CDI who showed improvement after 10 days of treatment were eligible. Recruitment began in November 2020, and follow-up was completed in October 2024. All participants initially received a standardized 2-week course of oral vancomycin at 125 mg four times daily. They were then randomized to either continue with a tapering schedule—125 mg twice daily for 7 days followed by 125 mg once daily for another 7 days—or to receive matching placebo capsules over the same period.
The primary endpoint was the probability that the extended pulse and taper regimen would be superior in preventing recurrence by day 56. Recurrence at day 38 was assessed as a secondary outcome. Bayesian generalized linear models were used to analyze binary outcomes.
Key Findings:
- The trial enrolled 265 participants but was stopped early due to recruitment challenges, limiting its statistical power.
- A total of 135 participants were randomized to the vancomycin taper group and 130 to the standard pulse group.
- The median age of participants was 63 years, and slightly more than half were women.
- By day 56, recurrence occurred in 14.8% of patients in the taper group compared with 17.7% in the standard pulse group (adjusted relative risk 0.84; 95% Bayesian credible interval 0.48–1.45), with a 73.8% posterior probability of superiority.
- At day 38, recurrence rates were 6.7% in the taper group and 15.4% in the control group (adjusted relative risk 0.43), corresponding to a 99.0% posterior probability of superiority.
- Adverse events were rare and occurred at similar rates in both groups.
The authors acknowledged several limitations, including early trial termination and potential diagnostic variability due to reliance on nucleic acid amplification testing. The use of a 14-day pulse in the control arm may also have reduced the apparent difference between groups. However, the findings indicate that a 4-week vancomycin pulse and taper regimen may help delay or prevent early CDI recurrence. Further large-scale, pragmatic trials—including direct comparisons with fidaxomicin and longer follow-up—are needed to refine optimal treatment strategies.
Reference:
McDonald EG, Butler-Laporte G, Brophy JM, et al. Initial Vancomycin Taper for the Prevention of Recurrent Clostridioides difficile Infection: A Randomized Clinical Trial. JAMA Netw Open. 2026;9(2):e2560495. doi:10.1001/jamanetworkopen.2025.60495
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.